AGLE - Aeglea BioTherapeutics GAAP EPS of -$0.37 revenue of $1.36B May, 05 2022 08:05 AM Aeglea BioTherapeutics Inc. Aeglea BioTherapeutics press release (NASDAQ:AGLE): Q1 GAAP EPS of -$0.37. Revenue of $1.36B. For further details see: Aeglea BioTherapeutics GAAP EPS of -$0.37, revenue of $1.36B